The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Jacqueline Elizabeth Shea net worth and biography

Jacqueline Shea Biography and Net Worth

COO of Inovio Pharmaceuticals

As Chief Operating Officer, Dr. Shea is responsible for INOVIO’s manufacturing, commercial, business development, and alliance management operations as well as serving as a key member of the executive team and forming and implementing overall corporate strategy.

Dr. Shea was previously the CEO at Aeras, the leading not for profit organization dedicated to developing new vaccines against the global number one infectious disease killer, tuberculosis (TB). She has more than 20 years’ experience in the life science industry, working across a range of R&D and senior commercial management roles. She joined Aeras in 2014 as the Chief Operating Officer before being promoted to CEO in 2015. During her tenure, Aeras delivered two major clinical breakthroughs in the development of TB vaccines. Prior to Aeras she spent eight years in a variety of senior management roles with Emergent BioSolutions, where from 2008 to 2013 she was General Manager and Vice President of The Oxford-Emergent Tuberculosis Consortium (OETC).

Dr. Shea initially trained as a molecular biologist and cell cycle geneticist and has spent much of her career dedicated to developing innovative products to prevent and treat infectious diseases. She holds twenty patents, is an author of numerous scientific publications and has served on multiple advisory boards. She received a BSc in Applied Biology from the University of Bath and a Ph.D. from the National Institute for Medical Research in the UK.

What is Jacqueline Elizabeth Shea's net worth?: The estimated net worth of Jacqueline Elizabeth Shea is at least $728.61 as of June 9th, 2021. Dr. Shea owns 149 shares of Inovio Pharmaceuticals stock worth more than $729 as of November 14th. This net worth estimate does not reflect any other investments that Dr. Shea may own. Additionally, Dr. Shea receives a salary of $1,130,000.00 as COO at Inovio Pharmaceuticals. Learn More about Jacqueline Elizabeth Shea's net worth.
How old is Jacqueline Elizabeth Shea?: Dr. Shea is currently 58 years old. There are 3 older executives and no younger executives at Inovio Pharmaceuticals. Learn More on Jacqueline Elizabeth Shea's age.
What is Jacqueline Elizabeth Shea's salary?: As the COO of Inovio Pharmaceuticals, Inc., Dr. Shea earns $1,130,000.00 per year. Learn More on Jacqueline Elizabeth Shea's salary.
How do I contact Jacqueline Elizabeth Shea?: The corporate mailing address for Dr. Shea and other Inovio Pharmaceuticals executives is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. Inovio Pharmaceuticals can also be reached via phone at (267) 440-4200 and via email at [email protected]. Learn More on Jacqueline Elizabeth Shea's contact information.
Has Jacqueline Elizabeth Shea been buying or selling shares of Inovio Pharmaceuticals?: Jacqueline Elizabeth Shea has not been actively trading shares of Inovio Pharmaceuticals within the last three months. Most recently, Jacqueline Elizabeth Shea sold 267 shares of the business's stock in a transaction on Wednesday, June 9th. The shares were sold at an average price of $1,441.44, for a transaction totalling $384,864.48. Following the completion of the sale, the chief operating officer now directly owns 149 shares of the company's stock, valued at $214,774.56. Learn More on Jacqueline Elizabeth Shea's trading history.
Who are Inovio Pharmaceuticals' active insiders?: Inovio Pharmaceuticals' insider roster includes Simon Benito (Director), Laurent Humeau (Insider), Peter Kies (CFO), Jong Kim (CEO), Jacqueline Shea (COO), David Weiner (Director), and Lota Zoth (Director). Learn More on Inovio Pharmaceuticals' active insiders.

Jacqueline Elizabeth Shea Insider Trading History at Inovio Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/9/2021	Sell	267	$1,441.44	$384,864.48	149
3/26/2021	Sell	32	$1,291.68	$41,333.76	500
3/12/2021	Sell	117	$1,448.64	$169,490.88	682
2/1/2021	Sell	196	$2,167.20	$424,771.20	464
1/28/2021	Sell	116	$1,733.76	$201,116.16	238

Jacqueline Elizabeth Shea Buying and Selling Activity at Inovio Pharmaceuticals

Inovio Pharmaceuticals Company Overview

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Today's Range

Now: $4.89

$4.86

$5.02

50 Day Range

MA: $5.83

$4.95

$6.82

2 Week Range

Now: $4.89

$4.20

$14.75

Volume

171,773 shs

Average Volume

399,353 shs

Market Capitalization

$126.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Financial Prophecy

From Porter & Company | Ad